TheraCryf held a Research and Development Day (R&DD) concentrating on the progress of SFX-01, its lead clinical asset in the study relating to glioblastoma at Erasmus University in the Netherlands, and on the two new candidates acquired in the Chronos acquisition. The Erasmus study is demonstrating very encouraging initial results with the drug on track for trial in humans by early 2026. The R&DD explained the differentiated potential in the Orexin and dopamine transporter (DAT) inhibitor programmes, each of which could be in clinic within 18 months, subject to funding. Sourcing non-dilutive funding is TheraCryf's current priority. We published an initiation on TheraCryf which sets out the full investment thesis on 20th May. Despite its advantages, TheraCryf trades on a fraction of the rating of most peers with similar characteristics, has multiple prospective newsflow events due in 2024/25, and has a financial runway through towards the end of FY26.
